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ABSTRACT
Objectives  To compare health-related quality of life 
(HRQoL) before and after treatment with etanercept in 
patients with moderate to severe rheumatoid arthritis 
(RA), psoriatic arthritis (PsA) and psoriasis using 
spydergram representations.
Methods  Data from randomised, controlled trials of 
etanercept in patients with RA, PsA and psoriasis were 
analysed. HRQoL was assessed by the medical outcomes 
survey short form 36 (SF-36) physical (PCS) and mental 
(MCS) component summary and domain scores. Baseline 
comparisons with age and gender-matched norms and 
treatment-associated changes in domain scores were 
quantiﬁ  ed using spydergrams and the health utility SF-6D 
measure.
Results  Mean baseline PCS scores were lower than 
age and gender-matched norms in patients with RA and 
PsA, but near normative values in patients with psoriasis; 
MCS scores at baseline were near normal in PsA and 
psoriasis but low in RA. Treatment with etanercept 
resulted in improvements in PCS and MCS scores as well 
as individual SF-36 domains across all indications. Mean 
baseline SF-6D scores were higher in psoriasis than in 
RA or PsA; clinically meaningful improvements in SF-6D 
were observed in all three patient populations following 
treatment with etanercept.
Conclusions  Patients with RA, PsA and psoriasis 
demonstrated unique HRQoL proﬁ  les at baseline. 
Treatment with etanercept was associated with 
improvements in PCS and MCS scores as well as 
individual domain scores in patients with RA, PsA and 
psoriasis.
Health-related quality of life (HRQoL) has been 
shown to be profoundly impaired in patients 
with bone and joint diseases, including rheuma-
toid arthritis (RA)1 and psoriatic arthritis (PsA).2–5 
HRQoL is also impaired in psoriasis but to a dif-
ferent degree, as reﬂ  ected by changes in the der-
matology life quality index and the Euro-QoL.6–12 
A prominent beneﬁ   t of treatment with tumour 
necrosis factor (TNF) antagonists in patients with 
these diseases has been an improvement in patient-
reported outcomes, including HRQoL.1 12–22
The medical outcomes survey short form 36 
(SF-36) is a generic patient-reported measure of 
HRQoL that has been validated for use in most 
rheumatic diseases, including RA1 23 and PsA24 25 
as well as psoriasis.26 27 It includes 36 questions 
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combined into eight domains, which are sum-
marised into physical component (PCS) and men-
tal component (MCS) summary scores.1 SF-6D is 
a health utility score based on mean scores across 
all eight domains of the SF-36, which has been 
demonstrated to be sensitive to change in rheu-
matic diseases.1 28–30 Importantly, SF-6D facilitates 
comparisons of baseline values and post-treatment 
changes in HRQoL.
The presentation and interpretation of HRQoL 
data from SF-36 is complex, and the impact of pat-
terns of disease and treatment-associated effects 
can be difﬁ  cult to evaluate. ‘Spydergrams’ provide 
an intuitive visual method to examine multiple 
domains of HRQoL simultaneously in a single 
ﬁ  gure.30 The objectives of this study were to use 
spydergrams to compare the impact on HRQoL 
of three different immune-mediated diseases, spe-
ciﬁ  cally in terms of how each disease differentially 
affects aspects of mental and physical wellbeing, 
and to use spydergrams to determine how etan-
ercept therapy impacts changes in domains of the 
SF-36 across these diseases.
Methods
Data for these analyses were obtained from ran-
domised controlled trials that have been published 
previously on patients with early RA (combina-
tion of methotrexate and etanercept in early RA; 
COMET),31–33 PsA (Study 160030)34 and psoriasis 
(Study 160042).17 Patients in COMET with early 
moderate to severe RA for a mean of 9 months 
were randomly assigned to receive etanercept (50 
mg a week) in combination with methotrexate or 
methotrexate alone for 52 weeks.31 Patients with 
PsA for a mean of approximately 9 years were ran-
domly assigned to receive etanercept (25 mg twice 
a week) or placebo for 24 weeks in Study 160030.34 
Patients with active, clinically stable plaque psoria-
sis for a mean of 20.5 years in Study 160042 were 
randomly assigned to treatment with etanercept 25 
mg twice a week or 50 mg twice a week or placebo 
for 12 weeks (randomised controlled trial portion 
of the trial).17 Patients in all arms of the psoriasis 
study received etanercept 25 mg twice a week 
open label for weeks 13–24.
In all studies, patients completed SF-36 question-
naires at baseline (before treatment) and at various 
protocol-speciﬁ  ed times during treatment. The eight 
domains of SF-36 (see supplementary ﬁ  gure  S1, 
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has been validated in RA and other rheumatic diseases with a 
minimally important difference (MID) of 0.041.29
The PCS and MCS component scores of SF-36 were initially 
assessed in each of the clinical trials and if the results of either 
were statistically signiﬁ  cant, mean changes in domains were 
assessed for statistical signiﬁ  cance without p value corrections, 
as customary, and for improvements meeting or exceeding the 
minimum clinically important difference (MCID) of 5–10 points 
for domain scores and 2.5–5 points for PCS and MCS scores.1 
These MCID values (which were established for RA patients) 
apply similarly to PsA and psoriasis.37 38 Similarly, MCID values 
have been estimated in psoriasis for PCS (0.51–3.91, best esti-
mate at 2.5) and MCS (3.89–6.61), which are in the range of the 
deﬁ  ned MCID we utilised.39 SF-6D MID was calculated based 
on the derivation by Ara and Brazier;28 29 recent data also indi-
cate that MID for RA and PsA are similar for the SF-6D.40
Baseline and treatment-associated improvements were quan-
tiﬁ  ed across all eight domains using spydergrams and health 
utility measure SF-6D. To generate the spydergrams, domain 
scores were plotted from 0 (worst) at the centre to 100 (best) 
at the outer edge. Demarcations along each axis/domain rep-
resent changes of 10 points, an estimated one to two times the 
MCID.30 Baseline and endpoint domain scores in each study 
were compared with age and gender-matched normative SF-36 
data from the USA.41
Results
Data for these analyses were obtained from 528 patients with 
RA, 205 patients with PsA and 583 patients with psoriasis 
(table 1). The majority of patients in all trials were white, most 
patients with RA were women, and most patients with psoriasis 
were men. All patients in the PsA trial also had psoriasis.
In RA patients enrolled in COMET, baseline PCS scores were 
low, approaching 2 SD below normative values of 50; MCS 
scores were more than 0.5 SD less than norms (table 2). After 52 
weeks of treatment, improvement in the PCS score was greater 
with the etanercept plus methotrexate combination therapy 
than with methotrexate alone (p=0.0031). Improvements in 
MCS with both treatments were large, exceeded the MCID, and 
approached normative values.
Large reductions in domain scores were reported by RA 
patients at baseline and were largest in RP and BP (ﬁ  gure 1A,B). 
After 52 weeks of treatment, statistically signiﬁ  cant (p<0.0001) 
and clinically meaningful improvements (≥MCID) across all 
domains were evident with both treatments. Greatest improve-
ments were seen in both treatment groups in domains with 
the lowest scores at baseline: RP (improvements of 46.5 vs 
40.8 points in the etanercept plus methotrexate vs methotrex-
ate arms), BP (37.2 vs 29.6 points) and RE (32.7 vs 25.9 points). 
Etanercept plus methotrexate therapy was associated with 
greater improvements in PF, BP and VT domains compared with 
methotrexate therapy alone (ﬁ  gure 1C).
Mean SF-6D scores in patients with RA at baseline (0.529) 
were considerably lower than age and gender-matched norms 
(0.822). Clinically meaningful improvements (≥MID) were 
observed in SF-6D scores in patients receiving etanercept plus 
methotrexate (mean score 0.658) and methotrexate alone (mean 
score 0.635). Improvements in SF-6D scores were signiﬁ  cantly 
greater in patients receiving etanercept plus methotrexate com-
pared with methotrexate alone (p=0.05).
In patients with PsA enrolled in Study 160030, baseline PCS 
scores were low in all patients, approaching 1.5 SD below the 
normative value of 50 (table 2). MCS scores approximated 
available online only) include: limitations in physical activities 
because of health problems (physical function (PF)); limitations 
in usual role activities because of physical health problems (role 
physical (RP)); bodily pain (BP); general health perceptions (GH); 
vitality (VT); limitations in social activities because of physical or 
emotional problems (social functioning (SF)); limitations in usual 
role activities because of emotional problems (role emotional 
(RE)); and psychological distress and wellbeing (mental health 
index (MH)), scored from 0 (worst) to 100 (best).35 Domain scores 
were normalised and z-transformed into PCS and MCS summary 
scores. PCS positively weights ﬁ  ve domains (PF, RP, BP, GH and 
VT) and negatively weights the remaining three domains (SF, RE 
and MH); MCS positively weights the four mental domains (VT, 
SF, RE and MH) and negatively weights the four physical domains 
(PF, RP, BP and GH). The normative value for the PCS or MCS 
summary score is 50 with a SD of 10.1
SF-6D estimates health utilities from SF-36 data to derive a 
single index score that ranges from 0 (death) to 1 (full health). 
SF-6D was initially based on individual patient data using 
answers to 11 items from the SF-36 questionnaire.36 SF-6D 
has recently been calculated based on group data using mean 
changes in each of the eight domains.28 29 This SF-6D calculation 
Table 1  Patient demographics and disease characteristics at baseline
 
RA 
(N = 528)
PsA 
(N = 205)
Psoriasis 
(N=583)
Sex, n (%)
  Men 141 (27) 105 (51) 382 (66)
  Women 387 (73) 100 (49) 201 (34)
Age, mean years (SD)    51.4 (0.6)*   47.4 (11.1)   45.2 (11.9)
  Range  18–84  18–76  18–87
Race/ethnicity, n (%)
  White 463 (88) 186 (91) 528 (91)
  Black/African-American   6  (1)   5  (2)   8  (1)
  Hispanic/Latino  27  (5)  11  (5)  19  (3)
  Other  32  (6)   3  (2)  28  (5)
Disease duration, mean
 RA   9.0  mos – –
  PsA –   9.1  yrs  –
  Psoriasis –  19.0  yrs  20.5  yrs
Previous therapies
  n (%) DMARD 113 (21) 156 (76)  –
  Psoriasis therapies – 147 (72) 516 (89)
Disease characteristics
    Tender joint count, 
mean no (SD)
 25.0  (14.5)†  21.3  (14.3)‡ –
    Swollen joint count, 
mean no (SD)
 17.3  (10.2)§  15.6  (10.6)** –
  PASI score,†† mean (SD) –   10.4 (10.7)‡‡   19.1 (8.5) 
   Psoriasis-affected  BSA, 
mean % (SD)
–  10.6  (15.4)  28.0  (17.4)
Patient-reported outcomes
  HAQ,§§ mean score (SD)     1.7 (0.7)     1.1 (0.6) –
  DLQI,¶ mean score (SD) – –  11.7  (6.8)
*Data represent mean (standard error) for patients with RA.
†71 possible joints.
‡78 possible joints.
§68 possible joints.
**76 possible joints.
††PASI scores range from 0 (no psoriasis) to 72 (severe disease).
‡‡PASI scores were only collected from psoriasis patients with affected BSA ≥3% 
(n=128).
§§HAQ scores range from 0 to 3.
¶DLQI scores range from 0 (no effect on patient’s life) to 30 (extremely large effect on 
patient’s life).
BSA, body surface area; DLQI, dermatology life quality index; DMARD, disease-
modifying antirheumatic drug; HAQ, health assessment questionnaire; PASI, psoriasis 
area and severity index; PsA, psoriatic arthritis; RA, rheumatoid arthritis.
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twice a week in the ﬁ  rst 12 weeks to 25 mg twice a week for the 
open-label phase of the trial. Patients who initially received pla-
cebo reported clinically meaningful improvements in both PCS 
and MCS after 12 weeks of receiving open-label etanercept.
Overall, patients with psoriasis reported lower reductions in 
physical and mental domains of SF-36 than patients with RA 
or PsA, and baseline SF-36 domain scores approximated normal 
values in most domains (ﬁ  gure 3A–C). The lowest scores were 
in the BP, GH, VT and MH domains. Despite high values at base-
line, after 12 weeks of treatment, improvements were reported 
in all domains and clinically meaningful improvements were 
reported in all domains except GH in patients receiving etaner-
cept at either dose. In both active treatment groups, the largest 
mean changes were reported in BP (14.6 points and 16.5 points 
for etanercept 25 mg twice a week and 50 mg twice a week, 
respectively), SF (8.9 points and 13.8 points), RP (9.8 points and 
13.1 points) and RE (10.5 points and 10.4 points) domains. No 
statistically signiﬁ   cant or clinically meaningful changes were 
reported in patients receiving placebo. During the open-label 
phase of the trial, patients who had initially received etaner-
cept at either dose maintained their improvements and patients 
who initially received placebo achieved clinically meaningful 
improvements in all domains but PF and GH (ﬁ  gure 3D–F).
The mean baseline SF-6D score was higher in patients with 
psoriasis (0.739) than in patients with RA or PsA, but was still 
less than age and gender-matched norms (0.854). Clinically 
meaningful improvements (≥MID) were observed in patients 
receiving active treatment but not in patients receiving placebo; 
in addition, during the open-label phase of the trial, improve-
ments were also reported in patients initially treated with pla-
cebo (table 2).
Discussion
Our data conﬁ  rm that HRQoL is much diminished in patients 
with PsA and RA compared with age and gender-matched 
norms. A very interesting observation from these data is that 
the baseline patterns of HRQoL reductions appear to be differ-
ent in each disease, as illustrated by the spydergrams. Patients 
normative values. After 24 weeks of treatment, patients receiving 
etanercept reported statistically signiﬁ  cant and clinically mean-
ingful improvements in both PCS (to within 0.5 SD of norms) 
and MCS (exceeding normative values) scores from baseline. 
Signiﬁ  cant improvements were not reported by patients receiv-
ing placebo.
Large reductions were reported in all domains of the SF-36 at 
baseline in patients with PsA (ﬁ  gure 2A,B); the most severely 
impacted domains were RP, BP and VT. After 24 weeks of treat-
ment, statistically signiﬁ  cant and clinically meaningful improve-
ments in all domains were reported by patients receiving 
etanercept (p<0.0001 for all domains except RE, p=0.004); the 
greatest improvements were in the physical domains RP (25.8 
points), BP (23.4 points) and PF (20.4 points). Patients receiving 
placebo reported statistically signiﬁ   cant and clinically mean-
ingful improvements in PF (4.2 points), BP (5.8 points), VT (4.5 
points) and SF (5.6 points). Etanercept therapy was associated 
with greater improvements across all domains compared with 
placebo (ﬁ  gure 2C).
Mean SF-6D scores in patients with PsA (0.651) were consid-
erably lower than age and gender-matched norms (0.848). After 
24 weeks of treatment, clinically meaningful improvements in 
SF-6D scores were reported by patients receiving etanercept 
(mean score 0.767) but not placebo (mean score 0.659).
In patients with psoriasis enrolled in Study 160042, baseline 
PCS scores were high in all patients and approximated norma-
tive values of 50; MCS scores were within less than 0.5 SD of 
norms (table 2). After 12 weeks of treatment, statistically signiﬁ  -
cant improvements in both PCS and MCS scores were observed 
in patients receiving etanercept at both doses (p<0.0001) but 
not in patients receiving placebo. Despite high baseline values, 
treatment-associated improvements in PCS and MCS scores 
exceeded MCID and resulted in ﬁ   nal scores that exceeded 
normative values. During weeks 13–24 of the study, when all 
patients received open-label etanercept at 25 mg twice a week, 
patients who had received etanercept during weeks 1–12 main-
tained their improvements in PCS and MCS scores, even in the 
treatment arm in which the dosage was reduced from 50 mg 
Table 2  Mean baseline and post-treatment SF-36 PCS and MCS scores and SF-6D scores across trials
RA PsA Psoriasis
Weeks 1–12 Weeks 13–24 (ETN 25 mg)*
  ETN + MTX MTX ETN Placebo ETN 25 mg ETN 50 mg Placebo ETN 25 mg ETN 50 mg Placebo
PCS
 Baseline 29.3 29.5 33.6 33.4 49.5 48.8 49.0 – – –
 Endpoint 43.0 40.2 43.4 34.7 52.8 52.7 49.6 52.9 52.5 52.0
 Mean  change  13.8† 10.9† 9.7† 1.5 3.3† 3.9† 0.7 3.4† 3.7† 3.1†
 p  Value‡ 0.003 NS 0.001 NS <0.0001 <0.0001 NS
MCS
 Baseline 42.1 42.2 51.5 49.3 48.4 47.2 46.1 – – –
 Endpoint 48.9 48.3 54.1 50.3 51.0 50.6 46.5 51.1 51.4 49.1
 Mean  change 6.9† 5.8† 2.6† 0.8 2.6† 3.4† 0.3 2.7† 4.2† 3.0†
 p  Value‡ NS NS 0.040 NS <0.0001 <0.0001 NS
SF-6D 
 Baseline 0.530 0.528 0.660 0.642 0.754 0.734 0.728 – – –
 Endpoint 0.658 0.635 0.767 0.659 0.819 0.822 0.739 0.822 0.821 0.808
 Mean  change 0.128 0.121 0.105 0.018 0.065 0.084 0.011 0.066 0.083 0.077
 p  Value‡ <0.0001 <0.0001 <0.0001 0.079 <0.0001 <0.0001 0.285      
*All patients received etanercept 25 mg twice a week during weeks 13–24, column headers represent original treatment assignment, p values are comparisons with week 12 values.
†Changes were greater than or equal to the minimal clinically important difference (MCID).
‡p Value for change from baseline.
ETN, etanercept; MCS, mental component summary; MTX, methotrexate; NS, not signiﬁ  cant; PCS, physical component summary; PsA, psoriatic arthritis; RA, rheumatoid arthritis; 
SF-36, short form 36; SF-6D, health utility score based on mean scores across all eight domains of the SF-36.
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(RE and SF domains) in RA. In contrast, psoriasis has a rela-
tively greater impact on mental rather than physical domains, 
as patients with psoriasis report the effect of their disease on 
with arthritis (either RA or PsA) reported an impact of disease 
on physical function (RP and PF domains), pain (BP) and fatigue 
(VT). These further affect emotional and social functioning 
Figure 1  Short form 36 (SF-36) spydergrams for patients with rheumatoid 
arthritis. Mean SF-36 scores at baseline and week 52 and age and 
gender-matched norms are shown for patients receiving (A) methotrexate 
or (B) etanercept plus methotrexate. (C) Mean SF-36 scores at baseline 
and week 52 for patients treated with methotrexate or etanercept plus 
methotrexate are compared. Mean SF-36 scores for age and gender-
matched norms are also shown. BP, bodily pain; ETN, etanercept; GH, general 
health; MH, mental health; MTX, methotrexate; PF, physical function; RE, role 
emotional; RP, role physical; SF, social functioning; VT, vitality.
Figure 2  Short form 36 (SF-36) spydergrams for patients with 
psoriatic arthritis. Mean SF-36 scores at baseline and weeks 4, 12 and 
24, and age and gender-matched norms are shown for patients receiving 
(A) placebo or (B) etanercept. (C) Mean SF-36 scores at baseline and 
week 24 for patients treated with placebo or etanercept are compared. 
Mean SF-36 scores for age and gender-matched norms are also shown. 
BP, bodily pain; ETN, etanercept; GH, general health; MH, mental health; 
PF, physical function; PL, placebo; RE, role emotional; RP, role physical; 
SF, social functioning; VT, vitality.
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objective measures of disease, relatively large changes in skin 
disease are required in order to register a change in the SF-36 
physical domain scores in psoriasis.19 42 In addition, comparison 
of all diseases by spydergrams reveals characteristic ‘notches’ in 
domains for a given disease. These domain deﬁ  cits unique to 
a particular disease should focus future research on the vari-
ables associated with these changes and how these might be 
more effectively addressed. A limitation in comparing HRQoL 
across diseases includes the duration of disease in the popula-
tions in these analyses; the mean duration of disease at baseline 
was 9 months, 9 years and approximately 20 years for patients 
social functioning (RE and SF), and to a lesser degree on physi-
cal function (RP) and pain (BP) domains. This is consistent with 
data obtained from large clinical trials in psoriasis. This sug-
gests that the impact of physical wellbeing on mental health 
might well depend on the nature of the physical impairment 
(eg, skin versus joint), as skin disease may have a dispropor-
tionally large effect on mental function and ensuing quality of 
life. Another explanation for the apparently small diminution in 
physical domains in psoriasis is that the SF-36 is not a particu-
larly sensitive measure of skin disease in psoriasis—although 
changes in the physical domains correlate with changes in 
Figure 3  Short form 36 (SF-36) spydergrams for patients with psoriasis. Mean SF-36 scores at baseline and week 12 of the randomised controlled 
trial (RCT) portion of the clinical trial and age and gender-matched norms are shown for patients receiving (A) placebo, (B) etanercept 25 mg 
twice a week (BIW), or (C) etanercept 50 mg twice a week. Mean SF-36 scores at baseline and weeks 12 and 24 of the open-label (OL) portion of 
the trial (when all patients received etanercept 25 mg twice a week) are shown for patients who had received (D) placebo, (E) etanercept 25 mg 
twice a week, or (F) etanercept 50 mg twice a week during the RCT portion of the trial. Mean SF-36 scores for age and gender-matched norms are 
also shown.
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differ from some earlier studies in which the control population 
was not appropriately matched to the study group. For some 
domains (eg, BP), post-treatment values actually exceeded those 
of the age-matched controls, suggesting that some aspects of 
with RA, PsA and psoriasis, respectively, with broad ranges. 
Clearly, this variability may have a signiﬁ  cant impact on per-
ceptions of disease and therefore HRQoL reported before and 
after treatment.
Because the age and gender-matched norms were very similar 
to one another in all three diseases, we were able to compare 
all baseline SF-36 domain scores in one spydergram (ﬁ  gure 4). 
The magnitude of reduction in disease compared with age and 
gender-matched normative values in domain scores was great-
est in RA followed by PsA, and of overall lesser magnitude in 
psoriasis. While the physical health domain scores were much 
lower in PsA than in psoriasis, mental health domain scores 
were very similar in the two diseases except for VT, which was 
substantially lower in PsA. This is consistent with the theory 
that much of the negative mental impact in PsA is caused by 
skin disease.43 Given that reports in the literature support the 
connection between educational status and negative mental 
impact of disease in arthritis, this might have implications for 
educational interventions to prevent the same negative mental 
impacts in psoriasis.
While it is easy to understand the diminished social and emo-
tional functioning in arthritis (RA and PsA) caused by physical 
limitation and pain, it may be difﬁ  cult immediately to ratio-
nalise why patients with psoriasis have diminished physical 
health. However, pain and itching from skin disease are known 
to result in inability to function in the workplace, use one’s 
hands (as palm involvement is common in psoriasis), and can 
result in sleep disturbances that characterise psoriasis and result 
in inability to participate in various physical activities related 
to work or leisure. In addition, it is known that psychological 
comorbidities such as depression and anxiety are associated 
with psoriasis. Our data suggest that the physical and mental 
domains of HRQoL are connected. Diminished mental health 
in psoriasis may result from concern over the appearance of the 
psoriatic skin, leading to anxiety, a sense of stigmatisation and 
embarrassment, reduction in participation in work and leisure 
activities and diminishment of a patient’s psychological wellbe-
ing. The mental and physical domains in psoriasis might also 
be uniquely connected by bodily pain. BP is consistently found 
to be among the most affected physical domains in psoriasis, 
which is likely to be due to skin pain from psoriatic plaques, as 
objective measures of skin disease tend to correlate well with 
the BP subscale.4 Pain and itching of the skin can cause both 
emotional and physical distress. Physical health may be affected 
by the itching and burning sensation of the skin and by joint pain 
in those with concomitant arthritis.9 12 Interestingly, depression 
also impacts BP in psoriasis.21 In addition, skin pain (and itching) 
probably contributes to sleep disturbance, which is an impor-
tant component of mental HRQoL in psoriasis. Sleep distur-
bance could directly contribute to fatigue and social function. BP 
has often been seen to be prone to greatest improvements of all 
SF-36 domains following therapy in psoriasis patients, and this 
is consistent with our data.20 It is of note that this improvement 
has been seen with a number of therapies, including anti-TNF 
therapies, ustekinumab (which targets interleukins 12 and 23)42 
and efalizumab (which targets CD11a).44 It has also recently 
been shown that depression impacts heavily on the BP domain 
in psoriasis,21 and this may be more uniquely associated with 
psoriasis than with RA or PsA.
Following treatment with etanercept, the largest improve-
ments were seen in physical domains as well as RE in RA 
patients. In patients with psoriasis, despite potential ceiling 
effects, treatment-associated changes could still be demon-
strated. Our ﬁ  ndings were similar to those of Revicki et al12 but 
Figure 4  Comparison of health-related quality of life (HRQoL) across 
indications. (A) Mean short form 36 (SF-36) scores for patients with 
rheumatoid arthritis (RA), psoriatic arthritis (PsA), or psoriasis (PsO) at 
baseline and average age and gender-matched norms for all indications 
are shown. (B) Mean SF-36 values at endpoint are shown for patients 
with RA (etanercept (ETN) plus methotrexate (MTX)-treated patients at 
week 52), PsA (etanercept-treated patients at week 24), and psoriasis 
(etanercept 50 mg twice a week (BIW)-treated patients at week 12) with 
average age and gender-matched norms for all indications. (C) Mean 
SF-36 scores at baseline for age and gender-matched norms are shown.
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chronic skin disease/pain might extinguish other pain stimuli to 
some degree so that when treated, patients actually feel less pain 
than norms.
A unique aspect of the SF-36 is that lower domain scores rep-
resent worse disease. This paper demonstrates that these lower 
domain scores are often associated with the largest treatment-
associated changes towards improvement. The use of spyder-
grams made this evident, as treatment was associated with loss 
of ‘notching’ and more even ‘rounding’ of the spydergram pat-
terns for both RA and PsA (compare ﬁ  gure 4A,B). In contrast, 
improvements are less easily demonstrated using the health 
assessment questionnaire disability index that also assesses 
physical function probably because higher scores indicate worse 
outcome. In addition, SF-36 data are normalised; this scoring 
method inherently leads to fewer ﬂ  oor (or ceiling) effects, as is 
evident in both RA and PsA datasets.
SF-6D scores are a means for quantifying changes illustrated 
in the spydergrams. As in patients with RA and PsA, SF-36 is 
a useful tool for assessing HRQoL in patients with psoriasis. 
Questions in the SF-36 may be less sensitive to the impact of 
skin disease in the absence of arthritis; however, statistically sig-
niﬁ  cant and clinically meaningful treatment-associated improve-
ments were demonstrated in psoriasis patients. Furthermore, 
our results illustrated less potential for ‘ceiling effects’ with this 
instrument, as reﬂ  ected in improvements that exceeded nor-
mative values even with high domain scores at baseline as in 
psoriasis.
Several domains from SF-36, a generic HRQoL assessment 
tool, have been shown to correspond with items from disease-
speciﬁ  c tools, such as the dermatology life quality index for 
psoriasis26 38 39 and the health assessment questionnaire for 
RA45 46 and PsA.37 In both research and clinical settings, visual 
representation of SF-36 data in spydergram format would 
be most useful for measuring improvements or changes in 
response to treatment in a cohort of patients. In clinical prac-
tice, spydergrams would also be useful for routine monitor-
ing of the mental domains of HRQoL. In addition to normal 
physical examinations of joints and/or skin, patient-reported 
information from SF-36 would complement physical ﬁ  ndings 
to provide the clinician with a more comprehensive evaluation 
of each patient.
Conclusions
In this study we directly compared HRQoL in patients with RA, 
PsA and psoriasis and showed that each disease had a unique 
proﬁ  le among physical and mental health domains. There were 
differences in the magnitude of change between the three dis-
eases, but not in the ability of RA, PsA and psoriasis patients to 
achieve HRQoL improvements. Similar to other studies using 
anti-TNF agents, we showed that improvements are achieved in 
response to therapy in both physical and mental health compo-
nents of the SF-36 in all three diseases.
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